Keywords: pozen, deal, gsk, new, migraine, drug, glaxosmithkline

Pozen deal with GSK on new migraine drug

Article | 23 June 2003

Print This

GlaxoSmithKline, Europe's leading drugmaker, has signed a licensing deal with USA-based drug development concern Pozen that could be worth as ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in